CORD-19:02a37452d5c5906b46021fbfa99a96df71704b65 / 15470-15721 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T72","span":{"begin":0,"end":251},"obj":"Sentence"},{"id":"TextSentencer_T72","span":{"begin":0,"end":251},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The latter has been achieved using a pharmacological antagonist, trapidil, which decreased the extent of oligodendrocyte remyelination of lysolecithin-induced demyelination in rats following systemic delivery (McKay et al., 1997; McKay et al., 1998) ."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T72","span":{"begin":0,"end":251},"obj":"Sentence"}],"text":"The latter has been achieved using a pharmacological antagonist, trapidil, which decreased the extent of oligodendrocyte remyelination of lysolecithin-induced demyelination in rats following systemic delivery (McKay et al., 1997; McKay et al., 1998) ."}

    CORD-19-PD-HP

    {"project":"CORD-19-PD-HP","denotations":[{"id":"T16","span":{"begin":159,"end":172},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0011096"}],"text":"The latter has been achieved using a pharmacological antagonist, trapidil, which decreased the extent of oligodendrocyte remyelination of lysolecithin-induced demyelination in rats following systemic delivery (McKay et al., 1997; McKay et al., 1998) ."}